Gossamer Bio Inc (GOSS)

Currency in USD
0.158
+0.001(+0.57%)
Closed·
0.154-0.004(-2.54%)
·
GOSS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.1510.164
52 wk Range
0.1143.870
Key Statistics
Prev. Close
0.157
Open
0.158
Day's Range
0.151-0.164
52 wk Range
0.114-3.87
Volume
6.7M
Average Volume (3m)
25.29M
1-Year Change
-91.8974%
Book Value / Share
-0.19
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GOSS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
1.656
Upside
+948.10%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Gossamer Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral

Analyst Ratings

3 Buy
3 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 1.656
(+948.10% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Piper Sandler
Buy4.00+2,431.65%15.00MaintainAug 14, 2026
Leerink
Buy1.00+532.91%-UpgradeJul 28, 2026
H.C. Wainwright
Buy2.00+1,165.82%5.00MaintainJun 26, 2026
Barclays
Sell0.28+77.22%0.30MaintainMay 19, 2026
Cantor Fitzgerald
Hold---DowngradeMar 23, 2026

Gossamer Bio Inc Earnings Call Summary for Q1/2026

  • Gossamer Bio Q1 revenue hit $16.96M, beating $4.71M forecast by 260%, but EPS of -$0.20 missed -$0.17 estimate by 17.65%.
  • Stock plunged 41.44% after-hours before recovering 12.09% premarket to $0.20, near 52-week low of $0.16 amid high volatility.
  • Company implemented 50% workforce reduction and debt restructuring to extend cash runway into Q1 2027 with $99M on hand.
  • Management maintains focus on seralutinib NDA submission targeted for September 2026 despite profitability challenges.
  • CFO Giraudo highlighted debt restructuring strengthens balance sheet; CEO Gujrathi emphasized strategic cost management for long-term goals.
Last Updated: 2026-05-21, 05:34 p/m
Read Full Transcript

Earnings

Latest Release
Aug 13, 2026
EPS / Forecast
-0.08 / -0.12
Revenue / Forecast
9.24M / 4.28M
EPS Revisions
Last 90 days

GOSS Income Statement

Compare GOSS to Peers and Sector

Metrics to compare
GOSS
Peers
Sector
Relationship
P/E Ratio
−0.6x−2.6x−0.3x
PEG Ratio
0.10−0.040.00
Price/Book
−0.8x4.7x2.6x
Price / LTM Sales
1.4x52.7x3.1x
Upside (Analyst Target)
-100.2%48.5%
Fair Value Upside
Unlock−5.5%6.3%Unlock

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
26.63M5.45%4.17M
Other Institutional Investors
552.82M94.55%86.57M
Public Companies & Retail Investors
0.000.00%0.00
Total
579.45M100.00%90.74M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Context Partners Master Fund, L.P.9.99%48,835,7887,648
683 Capital Management, LLC8.08%39,504,4846,186

People Also Watch

14.05
REPL
-5.13%
11.71
KURA
-6.54%
11.06
RGNX
-7.99%
3.4500
VRAX
+8.49%

FAQ

What Is the Gossamer Bio (GOSS) Stock Price Today?

The Gossamer Bio stock price today is 0.158 USD.

What Stock Exchange Does Gossamer Bio Trade On?

Gossamer Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Gossamer Bio?

The stock symbol for Gossamer Bio is "GOSS."

What Is the Gossamer Bio Market Cap?

As of today, Gossamer Bio market cap is 77.730M USD.

What Is Gossamer Bio's Earnings Per Share (TTM)?

The Gossamer Bio EPS (TTM) is -0.650.

When Is the Next Gossamer Bio Earnings Date?

Gossamer Bio will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is GOSS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Gossamer Bio Stock Split?

Gossamer Bio has split 0 times.

How Many Employees Does Gossamer Bio Have?

Gossamer Bio has 162 employees.

What is the current trading status of Gossamer Bio (GOSS)?

As of Aug 20, 2026, Gossamer Bio (GOSS) is trading at a price of 0.158 USD, with a previous close of 0.157 USD. The stock has fluctuated within a day range of 0.151 USD to 0.164 USD, while its 52-week range spans from 0.114 USD to 3.870 USD.

What Is Gossamer Bio (GOSS) Price Target According to Analysts?

The average 12-month price target for Gossamer Bio is 1.656 USD, with a high estimate of 4 USD and a low estimate of 0.28 USD. 3 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +948.10% Upside potential.

What Is the GOSS Premarket Price?

GOSS's last pre-market stock price is 0.160 USD. The pre-market share volume is 728,630.000, and the stock has decreased by 0.003, or 1.910%.

What Is the GOSS After Hours Price?

GOSS's last after hours stock price is 0.154 USD, the stock has decreased by -0.004, or -2.540%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.